In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arachnova: The Patent Problem with Re-Indication Strategies

Executive Summary

Dynogen and Arachnova both independently thought up a new indication for an unapproved but soon-to-genericize Mitsubishi anti-depressant. They both filed use patents, then both licensed the same preclinical data from Mitsubishi. Suddenly revealed to each other, they're now arguing over who owns the IP--a sobering message for the increasing number of companies pursuing re-indication strategies.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts